Authors

Dr. Manja Epping

Partner

Read More

Dr. Anja Lunze, LL.M.

Partner

Read More

Matthew Royle, Ph.D.

Partner

Read More

Judith Krens

Partner

Read More
Authors

Dr. Manja Epping

Partner

Read More

Dr. Anja Lunze, LL.M.

Partner

Read More

Matthew Royle, Ph.D.

Partner

Read More

Judith Krens

Partner

Read More

29 April 2020 |

Everything biologic and biosimilar in-house counsel need to know about COVID-19

In the first session of our 2020 webinar series, we discussed the key responses to the COVID-19 pandemic in Europe and the United States that impact biologics and biosimilars.

Many of the top-selling drugs worldwide are biologics, and several companies are seeking to produce biosimilars to compete in these lucrative markets. However, they are facing a great deal of uncertainty due to ever-changing emergency policies aimed at addressing COVID-19.

In this session we focussed on critical developments impacting biologic and biosimilar companies, including:

  • regulatory responses and challenges in the US and Europe
  • changes in patent office policies and proceedings
  • developments in the court systems, and
  • dealing with contractual and supply chain issues.
Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

DNA helix
Life sciences & healthcare

Termination, force majeure and frustration – international perspectives on the life sciences sector

17 April 2020
QUICK READ

by multiple authors

Click here to find out more
Life sciences & healthcare

Biosimilars – The economics of biosimilars: Market access, pricing and legal considerations

17 December 2019

by Matthew Royle, Ph.D.

Click here to find out more
Life sciences & healthcare

Biosimilars - clearing the way for launch

22 September 2019

by multiple authors

Click here to find out more

Related events

There are no upcoming events